BioGeNe Series 2023: A Platform for Pharmaceutical, Biotechnology Professionals and Technology Providers (San Diego, United States - February 8-9, 2023) - ResearchAndMarkets.com

13 Dec 2022
www.businesswire.com
Microbial therapyImmunotherapyClinical Study
DUBLIN--(BUSINESS WIRE)--The "BioGeNe Series 2023" conference has been added to ResearchAndMarkets.com's offering.
The host is here with a platform for pharmaceutical, biotechnology professionals and technology providers to come together at the BioGeNe 2023 Confex on the 8th - 9th February 2023 in San Diego-USA to discuss advancements and solutions to the most critical challenges in the Biomarker, Microbiome and Genome engineering areas.
Drug discovery businesses have begun to invest in cutting-edge methods for biomarker discovery because of mounting demands related to the success rates of FDA-approved biomarkers and associated diagnostic tests.
Speakers are to discuss about Biomarker and Companion Diagnostics, Microbiome and Probiotics and Precision Medicine. In the past year, the genome editing sector has seen some impressive advancements in the fields of genome writing, base editing, and specific advancements in the treatments using Car-T cells and immunotherapy.
Numerous small innovative businesses are present in the market because of the growing emphasis on the development of probiotics products and drugs as well as human microbiome therapies.
Biomarker and Companion Diagnostics
Biomarker discovery/ development
Translational research
Clinical Biomarker
Biomarkers in IO and Neurological disorders
Pathology
Companion Diagnostics
Next Gen Microbiome and Probiotics
Microbiome discovery
Department of Biochemistry and Immunology
Microbiome science
Microbiology
Human microbiome
Drug discovery
Therapeutics
Complex - Chronic - Rare Disease
Artificial Intelligence and Machine Learning
What To Expect
Commercialization of CDx
Proteomics and Genomics based Biomarkers
Biomarker Drug Discovery and Assay Development
Effective Microbiome Therapeutics in Production
Role of the human skin microbiome in precision health
The increasing pro-bacterial beauty industry
Business collaborations- Regulations and Investments
Novel horizons in biomarker strategies,
Liquid biopsy-based disease detection
Current Multi-Omics analysis
Artificial Intelligence and Machine Learning
Gene expression Profiling in Precision Medicine
Multiplex Companion Diagnostics and Regulatory Guidelines
Design of clinical trials in CDx
Microbiome as a science and its clinical applications- skin, gut & women's health
Prebiotics, Probiotics and Postbiotics
Why Attend?
To share and exchange the recent trends and techniques in Personalized Medicine
Quality insights and cohesiveness of key issues and obstacles experienced by the healthcare providers while implementing Precision Medicine
Discover the different avenues in patient-centric care
Access a wide range of novel applications, innovative research, regulatory and policy development
Opportunity for one-on-one networking and extend professional competency with experts ranging from Government, Industry, Technology, Research and Healthcare providers
Be a part of the conversations via a panel discussion with a great lineup of experts
Who Should Attend:
Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:
Biomarker discovery/development, Translational Research, Clinical Biomarkers, Biomarkers in IO and Neurological disorders, Imaging Biomarkers, Pathology, Companion Diagnostics, Biomarker Imaging, Proteomics Biomarkers, Experimental Medicine, Data Science. Microbiome discovery, Department of Biochemistry and Immunology, Microbiome science, Microbiology, Biological Science, Gut Biology, Human microbiome, Drug discovery, Therapeutics, Immunotherapy
Industry: Pharma/Therapeutic Companies/Start Up's
CEOs, CMO's, CSO's, COO's, Presidents, Vice Presidents, Directors, Managing Directors, Head of Departments, Executive Leaders, Pharmacists, Oncologists, Immunologists, Geneticists, Principal Scientists, Big Data Scientists, Business Development, Regulatory and Policy Advisors, Diagnostic Laboratory Professionals, Global Leaders.
Departments: Oncology, Personalized medicine, Immunology, Molecular Biology, Genetics and genomic medicine, Molecular Medicine, Pharmacogenomics, Biotechnology
Academics: Universities, Research Institutes, Hospitals
Head of Departments, Professors, Lecturers, Senior Scientists, Researchers, Bioinformaticians
Departments: Oncology, Personalized medicine, Immunology, Molecular Biology, Genetics and genomic medicine, Molecular Medicine, Pharmacogenomics, Biotechnology
Speakers
Julius Goepp
Founder, CEO, Scaled Microbiomics
Maya Ivanjesku
Chief Scientific Officer, Dakota Biotech
Peter Leighton
Seth D. Crosby
Director, Research Collaborations, Washington University School of Medicine
Arun K. Bhunia
Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease
Emily Stein
Nicole M. Scott
CEO and Founder, Cybele Microbiome
Yug Varma
Larry Weiss
CEO and Founder, Persona Biome, Inc.
Leigh A. Frame
Associate Director, Resiliency & Well-being Center, Program Director, Integrative Medicine (INTM), Executive Director, Office of INTM & Health
Scott A. Jackson
Leader - Complex Microbial Systems Group, NIST - National Institute of Standards and Technology
Andrea Azcarate-Peril
Associate Professor of Medicine, Director, UNC Microbiome Core, School of Medicine, University of North Carolina at Chapel Hill
Shannon Muir
Co-director of the California Initiative to Advance Precision Medicine in the California Governor's Office of Planning and Research,
Global head Precision Medicine Diagnostics Novartis,
Manish Kohli
Huntsman Cancer Institute
Head of Translational Biomarkers, Parthenon Therapeutics
For more information about this conference visit https://www.researchandmarkets.com/r/2esiru
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.